Synthetic patentiflorin A analogs as antiviral agents

Overview

The present invention relates to patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.

  • Synthetic patentiflorin A analogs as antiviral agents
Commercialisation opportunities
technology licensing agreement
Problem addressed

HKBU has invented a new class of patentiflorin A analogs, the preparation of these compounds and new intermediates, and their use for treatment of viral infections, such as HIV, CoV, EBOV and AIV.

Innovation
  • The present invention relates to the arylnaphthalene glycoside derivatives, the process for their preparation, and their use as antiviral agents.
  • It provides methods for treating viral infections, such as HIV, coronaviruses, Ebola virus, Marburg virus and influenza viruses infections.
Key impact
  • Safe and effective antiviral agents against a wide-spectrum of viruses with low toxicity.
Application
  • A method for treatment of viral infections, such as HIV, CoV, EBOV and AIV.

Patent

  • US Patent No.: US11,638,713
Hong Kong Baptist University (HKBU)

Aspiring to be a leading, research-led, liberal arts University in Asia, Hong Kong Baptist University is committed to conducting world-leading investigations that extends the frontiers of knowledge, tackles global challenges and benefits the community at home and abroad. 

Pursuing research excellence is one of the priorities of the University’s Institutional Strategic Plan 2018-2028. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to the society. 

Enquiry
Related Innovations